User profiles for D. Montefiori
David C Montefiori, Ph.D.Duke University Medical Center Verified email at duke.edu Cited by 97500 |
[HTML][HTML] Defining the risk of SARS-CoV-2 variants on immune protection
…, VA Meliopoulos, VD Menachery, DC Montefiori… - Nature, 2022 - nature.com
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …
variants jeopardizes the protective antiviral immunity induced after infection or …
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
…, MS Seaman, JR Mascola, DC Montefiori - Journal of …, 2014 - Elsevier
… Many of the methods described in this report have been published previously (Montefiori,
2009). Detailed protocols and other supporting materials may be found at http://www.hiv.lanl.…
2009). Detailed protocols and other supporting materials may be found at http://www.hiv.lanl.…
The role of antibodies in HIV vaccines
JR Mascola, DC Montefiori - Annual review of immunology, 2009 - annualreviews.org
… Clades A, C, and D viruses predominate on the African continent, whereas most infections
in India and China derive from clade C viruses (30). Subtype B, which comprises most …
in India and China derive from clade C viruses (30). Subtype B, which comprises most …
[PDF][PDF] Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus
…, CC LaBranche, EO Saphire, DC Montefiori - Cell, 2020 - cell.com
A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
[HTML][HTML] A bivalent omicron-containing booster vaccine against Covid-19
…, Y Chang, A Sutherland, DC Montefiori… - … England Journal of …, 2022 - Mass Medical Soc
Background The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214
booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
[HTML][HTML] Immune-correlates analysis of an HIV-1 vaccine efficacy trial
…, SM Alam, DT Evans, DC Montefiori… - … England Journal of …, 2012 - Mass Medical Soc
Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations
…, SE O'Connell, DC Montefiori… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for
productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 …
productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 …
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8+ Lymphocytes
…, BJ Scallon, J Ghrayeb, MA Forman, DC Montefiori… - Science, 1999 - science.org
… 3D). The kinetics of the generation of this CTL response during primary SIVmac infection
was identical to that which we have observed in six other monkeys (14). In the Mamu A*01 + …
was identical to that which we have observed in six other monkeys (14). In the Mamu A*01 + …